Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine
NCT ID: NCT01373619
Last Updated: 2012-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2010-01-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ivabradine in Hemodialysed Patients With Increased Heart Rate
NCT01364077
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
NCT00202579
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure
NCT00757055
Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients
NCT03710057
Heart Rate Reduction in Heart Failure
NCT01178528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVABRADINE, HEART FAILURE WITH NORMAL EF
Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
Ivabradine
ivabradine titrated to 7.5 mg BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivabradine
ivabradine titrated to 7.5 mg BID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signs and symptoms of heart failure with normal ejection fraction
* sinus rhythm
Exclusion Criteria
* valvular heart disease
* unstable angina
* hospitalization for heart failure prior 3 months
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Campania Luigi Vanvitelli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Second University of Naples
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gennaro Cice, MD
Role: PRINCIPAL_INVESTIGATOR
University of Campania Luigi Vanvitelli
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chair of Cardiology Second Univesity of Naples
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HFNEF-IVA-DIAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.